Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 8/20 | 0.59 |
| ▸ | CTSK | P43235 | 7/20 | 0.59 |
| ▸ | CTSB | P07858 | 2/20 | 0.59 |
| ▸ | CTSL | P07711 | 1/20 | 0.59 |
| ▸ | ACE | P12821 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | AKT1 | P31749 | 1/20 | 0.52 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 2/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
| ▸ | REN | P00797 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5966540 | 1.00 | CTSS (0.59) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL5966545 | 1.00 | CTSS (0.59) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL13537631 | 0.91 | BCL2 (0.58) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL18607778 | 0.88 | PPARG (0.49) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL13537645 | 0.88 | CTSS (0.59) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL3431290 | 0.87 | ABCB1 (0.52) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL13537925 | 0.86 | PPARA (0.65) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL5115955 | 0.85 | ITGB3 (0.47) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL5115948 | 0.85 | ITGB3 (0.47) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL5110052 | 0.85 | ITGB3 (0.47) | CTSSCTSKCTSBCTSLACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9593073-B2 | Method for the preparation of diazoalkanes | BAKHU LIMITED (GB) | 2017-03-14 | — | — | US | disclosed |
| US-20150038687-A1 | METHOD FOR THE PREPARATION OF DIAZOALKANES | BAKHU LIMITED (GB) | 2015-02-05 | — | — | US | disclosed |
| US-5414013-A | Enzyme inhibitors | E. R. SQUIBB & SONS, INC. (US) | 1995-05-09 | — | — | US | disclosed |
| US-5414017-A | Cardiovascular agents | E. R. SQUIBB & SONS, INC. (US) | 1995-05-09 | — | — | US | disclosed |
| US-5223516-A | Endopeptidase inhibitors | E. R. SQUIBB & SONS, INC. (US) | 1993-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038687-A1 | METHOD FOR THE PREPARATION OF DIAZOALKANES | NIT2, DNTT, NAT1 | CTSS 3735/4885CTSK 1905/4885CTSB 3420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.